Atiratecan
| Structural formula | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||
| General | |||||||||||||
| Non-proprietary name | Atiratecan | ||||||||||||
| other names |
(9 S ) -9-ethyl-10,13-dioxo-1-pentyl-9,10,13,15-tetrahydro-1 H , 12 H -pyrano [3 ", 4": 6 ', 7'] indolizino [2 ', 1': 5.6] pyrido [4,3,2- de ] quinazolin-9-yl-glycyl- N -methylglycinate |
||||||||||||
| Molecular formula | C 31 H 34 N 6 O 6 | ||||||||||||
| External identifiers / databases | |||||||||||||
|
|||||||||||||
| Drug information | |||||||||||||
| Drug class | |||||||||||||
| properties | |||||||||||||
| Molar mass | 586 g · mol -1 | ||||||||||||
| safety instructions | |||||||||||||
|
|||||||||||||
| As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . | |||||||||||||
Atiratecan is an experimental drug that is being developed to treat cancer (e.g. pancreatic cancer , ovarian cancer , liver cancer ). The substance is structurally derived from the alkaloid camptothecin and is in the pre-clinical research phase.
literature
- Agent for preventing or treating pancreas cancer, ovary cancer or liver cancer containing novel water-soluble drug. PCT Int. Appl. 108pp, 2007
Individual evidence
- ↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.